Figure 5. BK40143 and BK40197 improve behavioral outcomes in animal models of proteinopathies.

(A, B) Male (blue) and female (red) 12-mo-old TgAPP mice tested via novel object recognition displayed significantly improved outcomes when treated with (A) 5 mg/kg BK40143 (P = 0.0003) or (B) 45 mg/kg BK40197 (P = 0.006) compared with DMSO-treated controls. (C, D, E, F) These mice also displayed improved recall during (C) Morris water maze training trials (P = 0.04), whereas mice treated with 5 mg/kg BK40143 showed similar improvements on (D, E, F) Morris water maze endpoint measures (time in correct quadrant: P = 0.02, quadrant entries: P = 0.03. platform latency: P = 0.05). (G, H, I, J) TgAPP mice treated with 45 mg/kg BK40197 (G) spend more time in the open arm of the elevated plus maze compared to DMSO-treated controls (P = 0.02). 12-mo-old A53T mice treated with 5 mg/kg BK40143 display improved outcomes on (H) novel object recognition (P = 0.03), while A53T mice treated with (I) 5 mg/kg BK40143 (P = 0.04) or (J) 45 mg/kg BK40197 (P = 0.05) showed significant improvements in nesting behavior.

Source data are available for this figure.